Post-mortem analysis of candida albicans breakthrough infection during echinocandin treatment in haematopoietic stem cell transplant recipient;Post-mortem analýza průlomové infekce Candida albicans při léčbě echinokandiny u pacienta po transplantaci kmenových buněk krvetvorby

Epidemiologie, Mikrobiologie, Imunologie

Volumn 63, Issue 2, 2014, Pages 121-124

  Chrenkova, V ^a   Hubacek, P ^a   Sedlacek, P ^a   Riha, P ^a   Kodetova, D ^a   Bebrova, E ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Echinocandin resistance; Haematopoietic stem cell transplant; Invasive candida di ase

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYTARABINE; ECHINOCANDIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ITRACONAZOLE; MELPHALAN; MICAFUNGIN; POSACONAZOLE; THYMOCYTE ANTIBODY; VORICONAZOLE; ANTIFUNGAL AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; ARTICLE; AUTOPSY; BLOOD CULTURE; CANDIDA ALBICANS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FUSION GENE; GASTROINTESTINAL HEMORRHAGE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE CANDIDIASIS; LEUKEMIA RELAPSE; LIVER TOXICITY; LUNG MYCOSIS; MELENA; MICROBIAL COLONIZATION; NAUSEA; NEUTROPENIC ENTEROCOLITIS; NONHUMAN; SACCHAROMYCES CEREVISIAE; VOMITING; ANTIFUNGAL RESISTANCE; CANDIDIASIS; CASE REPORT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; ISOLATION AND PURIFICATION; LEUKEMIA, MYELOID, ACUTE;

ADOLESCENT; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 84923370671     PISSN: 12107913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Arendrup MC, et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother, 2009;53(3):1185-1193.
2. Ascioglu S, et al. Defining opportunistic invasive fungal infections n immunocompromised patients with cancer and hematopoie-tic stem cell transplants: an international consensus. Clin Infect Dis, 2002;34(1):7-14.
3. Benjamin DK Jr. et al. Infections diagnosed in the first year after pe-diatric stem cell transplantation. Pediatr Infect Dis J, 2002;21(3):227-234
4. Campana D, Leung W. Clinical significance of minimal residual dise-ase in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br JHaematol, 2013;162(2):147-161.
5. Canton E, Espinel-Ingroff A, Peman, J. Trends in antifungal susceptibility testing using CLSI reference and commercial methods. Expert RevAnti Infect Ther, 2009;7(1): 107-119.
6. Castanheira M, et al. Low Prevalence of fks1 Hotspot 1 Mutations in a Worldwide Collection of Candida spp. Antimicrob Agents Chemother, 2010;54(6):2655-2659.
7. Douglas CM, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother, 1997;41(11):2471-2479
8. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother, 2009;53(1):112-122.
9. Hale KA, et al. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br JHaematol, 2010;149(2):263-272.
10. Herbrecht R, et al. Indications and outcomes of antifungal thera-py in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. J Antimicrob Chemother, 2012;67(11):2731-2738.
11. Hernandez S, et al. Caspofungin resistance in Candida albicans correlating clinicaloutcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004;48(4):1382-1383.
12. Hope WW, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin MicrobiolInfect, 2012;18(Suppl 7):38-52.
13. Horn DL, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis, 2009;48(12):1695-1703.
14. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabra-ta clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother, 2006;50(8): 2892-2894.
15. Khlif M, et al. Evaluation of nested and real-time PCR assays in the diagnosis of candidaemia. Clin Microbiol Infect, 2009;15(7):656-661
16. Kocmanova I, et al. Invasive candidiasis in selected heamatology departments in the Czech Republic and Slovakia microbiological re-sults of the CAN CELL project. Klin MikrobiolInfekc Lek, 2011;17(1):5-10
17. Laverdiere M, et al. Progressive loss of echinocandin activity fo-lowing prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother, 2006;57(4):705-708.
18. Maertens J, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant, 2011;46(5):709-1718.
19. Mor M, et al. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer, 2011;56(7):1092-1097.
20. Niimi K, et al. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J Antimicrob Chemother, 2010;65(5):842-852.
21. Park S, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother, 2005;49(8):3264-3273.
22. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat, 2007;10(3):121-130.
23. Pfeiffer CD, et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol, 2010;48(7):2373-2380.
24. Pongers-Willemse MJ, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leu-kemia using junctional region specific TaqMan probes. Leukemia, 1998;12(12):2006-2014.
25. Slater JL, et al. Disseminated candidiasis caused by Candida al-bicans with amino acid substitutions in Fks1 at position Ser645 can-not be successfully treated with micafungin. Antimicrob Agents Chemother, 2011;55(7):3075-3083.
26. Steinbach WJ, et al. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J, 2012;31(12):1252-1257.
27. Vella A, et al. Rapid antifungal susceptibility testing by matrix-as-sisted laser desorption ionization-time of flight mass spectrometry analysis. J Clin Microbiol, 2013;51(9):2964-2969.
28. White PL, Archer AE, Barnes RA. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol, 2005;43(5):2181-2187